Category - Developments

Developments

Senseonics and Ascensia receive FDA approval for world’s first CGM with 365-day sensor

Senseonics Holdings (NYSE:SENS) and closely-held Ascensia Diabetes Care herald a significant breakthrough in diabetes technology and management, announcing FDA approval of Eversense 365, the world’s first one-year...

September 18, 2024

Developments

PharmaJet and Scancell forge alliance to develop and commercialize needle-free DNA vaccine for advanced melanoma

Closely-held PharmaJet has announced a strategic partnership with Scancell Holdings (AIM:SCLP) to supply its Stratis Intramuscular (IM) Needle-free Injection System for delivery of Scancell’s advanced melanoma DNA...

September 17, 2024

Developments

Ripple and AbbVie launch strategic partnership to leverage eye care expertise and drug delivery innovation for next-gen glaucoma therapies

Closely-held Ripple Therapeutics has entered into a collaboration and option-to-lease agreement with AbbeVie (NYSE:ABBV) to develop RTC-620, a next generation, fully biodegradable, sustained-release drug delivery...

September 17, 2024

Developments

Profound’s PRO-Talk Live! 2024 spotlights the future of prostate disease care with TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) hosted its second PRO-Talk Live! educational event, by physicians for physicians, in Las Vegas this past weekend. The event featured a prestigious panel of experts, innovators...

September 16, 2024

Developments

Inspira secures additional U.S. patent approval for blood oxygenation system

Inspira Technologies (NASDAQ:IINN) has announced the approval of a second U.S. patent for VORTEX, its orbiting blood oxygenation delivery system designed to oxygenate blood without the use of fibre membranes, bringing...

September 16, 2024

Developments

Evaxion reports positive one-year Phase 2 data on personalized cancer vaccine

Evaxion Biotech (NASDAQ:EVAX) has announced positive one-year data from its Phase 2 trial of the AI-designed personalized cancer vaccine, EVX-01, a potential treatment for melanoma. The data, from a one-year interim...

September 16, 2024

Developments

Cidara’s workforce restructuring enables focus on clinical development

Cidara Therapeutics (NASDAQ:CDTX) has announced a planned workforce reduction, impacting approximately 30% of the company’s employees, enabling the company to reduce capital needs and concentrate on the clinical...

September 13, 2024

Developments

Tenon prepares to launch new joint fixation device with 30% reduction in implant width

Tenon Medical (NASDAQ:TNON) announced the limited alpha launch of its new Catamaran SE SI Joint Fusion System in early Q4. The company aims to gather initial user feedback from a select group of physicians to support a...

September 13, 2024

Developments

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

Aura Biosciences (NASDAQ:AURA) has announced positive Phase 2 end-of-study (EOS) results evaluating the safety, tolerability, and efficacy of bel-sar (AU-011) for the first-line treatment of early-stage choroidal...

September 12, 2024

Developments

Vor Bio reports data validating shielded transplants and early evidence of patient benefit

Vor Bio (NASDAQ:NOR) announced new data from its ongoing Phase 1/2 study of VBP101 in relapsed/refractory AML patients, demonstrating reliable engraftment, shielding from Mylotarg toxicity, a broadened therapeutic...

September 6, 2024

Category - Developments

Senseonics and Ascensia receive FDA approval for world’s first CGM with 365-day sensor

PharmaJet and Scancell forge alliance to develop and commercialize needle-free DNA vaccine for advanced melanoma

Ripple and AbbVie launch strategic partnership to leverage eye care expertise and drug delivery innovation for next-gen glaucoma therapies

Profound’s PRO-Talk Live! 2024 spotlights the future of prostate disease care with TULSA-PRO

Inspira secures additional U.S. patent approval for blood oxygenation system

Evaxion reports positive one-year Phase 2 data on personalized cancer vaccine

Cidara’s workforce restructuring enables focus on clinical development

Tenon prepares to launch new joint fixation device with 30% reduction in implant width

Aura announces positive Phase 2 EOS results evaluating bel-sar for CM

Vor Bio reports data validating shielded transplants and early evidence of patient benefit

General

More